Compare Medtronic PLC (MDT) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Msci Inc — how do they compare? Medtronic PLC trades at $82.59 (market cap $106.61B), while Msci Inc trades at $569.39 (market cap $45.51B). The key difference: Medtronic PLC is far larger — about 2.3× Msci Inc's market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| MDT | MSCI | |
|---|---|---|
Market Cap | $106.61B | $45.51B |
Sector | Health | Financials |
52-Week High | $105.35 | $643.83 |
52-Week Low | $73.75 | $511.84 |
Enterprise Value | $125.36B | $51.67B |
Dividend Yield | 3.46% | 1.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
MSCI trades at $625.11, down 0.56% on the day, with a bullish technical outlook supported by moving averages and a recent strategic partnership with UBS to enhance its private markets platform. The company shows strong fundamentals with a 40.74% net income margin and consistent earnings beats, though valuation ratios like a P/E of 35.9 suggest a premium. Analyst consensus is strongly bullish with a $723.38 price target, and cash flow turned positive in 2025 after prior years of net outflows.
The outlook for MSCI is positive, driven by earnings growth, high profitability, and strategic expansions, but risks include elevated debt levels and sensitivity to financial market conditions. The stock offers a dividend yield supported by solid cash generation, though investors should weigh the high valuation against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
